ProCE Banner Activity

Expanding the Role of PARP Inhibitors in Prostate Cancer—Innovative Combination Strategies

Clinical Thought
In this commentary, gain insights on the rationale for PARP inhibitor combinations in prostate cancer and the latest corresponding evidence available.

Released: July 02, 2021

Expiration: July 01, 2022

No longer available for credit.

Share

Faculty

Charles Ryan

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Charles Ryan, MD

Associate Clinical Professor
Department of Medicine Hematology/Oncology
University of California, San Francisco
San Francisco, California

Charles J. Ryan, MD, has disclosed that he has research support from Bayer, Clovis, and Sanofi/Genzyme and consulting fees from Advanced Accelerator Applications, Bayer, Dendreon, Pfizer, and Roivant.